Literature DB >> 25568646

Pain pharmacology: focus on opioids.

Diego Fornasari1.   

Abstract

The incidence of chronic pain is estimated to be 20-25% worldwide. Although major improvements in pain control have been obtained, more than 50% of the patients reports inadequate relief. It is accepted that chronic pain, if not adequately and rapidly treated, can become a disease in itself, often intractable and maybe irreversible. This is mainly due to neuroplasticity of pain pathways. In the present review I will discuss about pain depicting the rational for the principal pharmacological interventions and finally focusing on opioids, that represent a primary class of drug to treat pain.

Entities:  

Keywords:  chronic pain; multi-target pharmacology; opioids; tapentadol

Year:  2014        PMID: 25568646      PMCID: PMC4269136     

Source DB:  PubMed          Journal:  Clin Cases Miner Bone Metab        ISSN: 1724-8914


  13 in total

Review 1.  Pain: moving from symptom control toward mechanism-specific pharmacologic management.

Authors:  Clifford J Woolf
Journal:  Ann Intern Med       Date:  2004-03-16       Impact factor: 25.391

Review 2.  Combination pharmacotherapy for the treatment of neuropathic pain in adults.

Authors:  Luis Enrique Chaparro; Philip J Wiffen; R Andrew Moore; Ian Gilron
Journal:  Cochrane Database Syst Rev       Date:  2012-07-11

3.  Basic opioid pharmacology: an update.

Authors:  Hasan Pathan; John Williams
Journal:  Br J Pain       Date:  2012-02

Review 4.  Noradrenergic reuptake inhibition in the treatment of pain.

Authors:  Craig T Hartrick
Journal:  Expert Opin Investig Drugs       Date:  2012-10-08       Impact factor: 6.206

Review 5.  Opioids for chronic pain: new evidence, new strategies, safe prescribing.

Authors:  Oscar A de Leon-Casasola
Journal:  Am J Med       Date:  2013-03       Impact factor: 4.965

Review 6.  Neuropathic pain.

Authors:  M Koltzenburg; J Scadding
Journal:  Curr Opin Neurol       Date:  2001-10       Impact factor: 5.710

Review 7.  Central mechanisms of pathological pain.

Authors:  Rohini Kuner
Journal:  Nat Med       Date:  2010-10-14       Impact factor: 53.440

Review 8.  Pain mechanisms in patients with chronic pain.

Authors:  Diego Fornasari
Journal:  Clin Drug Investig       Date:  2012-02-22       Impact factor: 2.859

Review 9.  Transient receptor potential channels: targeting pain at the source.

Authors:  Ardem Patapoutian; Simon Tate; Clifford J Woolf
Journal:  Nat Rev Drug Discov       Date:  2009-01       Impact factor: 84.694

10.  Chronic back pain is associated with decreased prefrontal and thalamic gray matter density.

Authors:  A Vania Apkarian; Yamaya Sosa; Sreepadma Sonty; Robert M Levy; R Norman Harden; Todd B Parrish; Darren R Gitelman
Journal:  J Neurosci       Date:  2004-11-17       Impact factor: 6.167

View more
  10 in total

1.  Health Care Utilization and Costs Associated with Nausea and Vomiting in Patients Receiving Oral Immediate-Release Opioids for Outpatient Acute Pain Management.

Authors:  Elizabeth Marrett; Winghan Jacqueline Kwong; Feride Frech; Chunlin Qian
Journal:  Pain Ther       Date:  2016-10-04

Review 2.  Pharmacotherapy for Neuropathic Pain: A Review.

Authors:  Diego Fornasari
Journal:  Pain Ther       Date:  2017-11-24

3.  Role of μ-opioid receptor in parafascicular nucleus of thalamus on morphine-induced antinociception in a rat model of acute trigeminal pain.

Authors:  Esmaeal Tamaddonfard; Amir Erfanparast
Journal:  Vet Res Forum       Date:  2017-03-15       Impact factor: 1.054

4.  Characterizing non-heroin opioid overdoses using electronic health records.

Authors:  Amelia J Averitt; Benjamin H Slovis; Abdul A Tariq; David K Vawdrey; Adler J Perotte
Journal:  JAMIA Open       Date:  2019-11-26

Review 5.  ALIAmides Update: Palmitoylethanolamide and Its Formulations on Management of Peripheral Neuropathic Pain.

Authors:  Ramona D'Amico; Daniela Impellizzeri; Salvatore Cuzzocrea; Rosanna Di Paola
Journal:  Int J Mol Sci       Date:  2020-07-27       Impact factor: 5.923

Review 6.  Pharmacological rationale for tapentadol therapy: a review of new evidence.

Authors:  Patrizia Romualdi; Mariagrazia Grilli; Pier Luigi Canonico; Massimo Collino; Anthony H Dickenson
Journal:  J Pain Res       Date:  2019-05-16       Impact factor: 3.133

Review 7.  Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls.

Authors:  Marie-Line Reynaert; Denis Dupoiron; Edouard Yeramian; Laurent Marsollier; Priscille Brodin
Journal:  Toxins (Basel)       Date:  2019-09-04       Impact factor: 4.546

8.  Acute Tramadol-Induced Cellular Tolerance and Dependence of Ventral Tegmental Area Dopaminergic Neurons: An In Vivo Electrophysiological Study.

Authors:  Shabnam Khodayari; Firouz Ghaderi Pakdel; Parviz Shahabi; Somayyeh Naderi
Journal:  Basic Clin Neurosci       Date:  2019-05-01

9.  Tapentadol extended release for the management of chronic neck pain.

Authors:  Domenico Billeci; Flaminia Coluzzi
Journal:  J Pain Res       Date:  2017-03-02       Impact factor: 3.133

10.  Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment.

Authors:  Helene Cabanas; Katsuhiko Muraki; Natalie Eaton-Fitch; Donald Ross Staines; Sonya Marshall-Gradisnik
Journal:  Front Immunol       Date:  2021-07-13       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.